Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2023 Readersâ Choice Winners
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immuron Ltd ADR
(NQ:
IMRN
)
2.630
-0.150 (-5.40%)
Streaming Delayed Price
Updated: 3:55 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immuron Ltd ADR
< Previous
1
2
3
4
5
Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Today 8:06 EDT
Via
Benzinga
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 11, 2024
Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Intraday Session
March 11, 2024
Via
Benzinga
Immuron welcomes launch of Travelan on Amazon US
July 26, 2023
--News Direct--
Via
News Direct
Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
March 11, 2024
Shares of Fangdd Network Group Ltd. (NASDAQ: DUO) rose sharply in today’s pre-market trading after the company announced its 2024 strategic layout with plans to enter the real estate stock asset...
Via
Benzinga
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 08, 2024
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
March 08, 2024
Via
Benzinga
Why Porch Group Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
March 08, 2024
Shares of Porch Group, Inc. (NASDAQ: PRCH) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
March 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 07, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
March 07, 2024
Pre-market stock movers are worth checking out on Thursday to get an idea of the hottest stocks worth watching this morning!
Via
InvestorPlace
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
March 07, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron Presentation Australian Biologics Festival 2024
February 21, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron achieves record Travelan® sales
February 13, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
February 08, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron achieves record half yearly Travelan® sales
January 16, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron Clinical Trials Update
December 22, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
December 04, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
November 28, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO Steven Lydeamore Investor Webinar Presentation
November 13, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO Steven Lydeamore presented at AusBioInvest
October 30, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Announces Travelan® Clinical Study Cohort 2 commences
October 18, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron achieves record quarterly Travelan® sales
October 11, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron hails record monthly sales of Travelan
September 14, 2023
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its over-the-counter gastrointestinal supplement Travelan®....
Via
TheNewswire.com
Immuron hails record monthly sales of Travelan
September 14, 2023
--News Direct--
Via
News Direct
Immuron achieves record monthly Travelan® sales
September 13, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright
September 11, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron to present at the Military Health System Research Symposium
August 14, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron welcomes launch of Travelan on Amazon US
July 26, 2023
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) chief commercial officer Flavio Palumbo speaks with Proactive following the news its Travelan product has launched on Amazon US.
Via
TheNewswire.com
Immuron Announces First Patients Enrolled in Travelan® Clinical Study
July 25, 2023
From
Immuron Limited
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.